<DOC>
	<DOC>NCT00397930</DOC>
	<brief_summary>RATIONALE: Yoga may help improve sleep, fatigue, and quality of life in cancer survivors. PURPOSE: This phase II trial is studying how well yoga works in treating sleep disturbance in cancer survivors.</brief_summary>
	<brief_title>Yoga in Treating Sleep Disturbance in Cancer Survivors</brief_title>
	<detailed_description>OBJECTIVES: Primary - Determine the efficacy of Hatha yoga in improving sleep quality in cancer survivors experiencing persistent sleep disturbance. OUTLINE: This is a randomized, multicenter study. Patients are stratified according to gender and sleep disturbance rating reported on the eligibility assessment questionnaire (≤ 5 vs &gt; 5). Patients are randomized to 1 of 2 arms. - Arm I: Patients receive standard care for 6 weeks. Patients may switch to the yoga intervention immediately after study completion. - Arm II:Patients receive standard care for 2 weeks, followed by two 75-minute sessions of Hatha yoga per week for 4 weeks. PROJECTED ACCRUAL: A total of 400 patients will be accrued for this study.</detailed_description>
	<mesh_term>Fatigue</mesh_term>
	<mesh_term>Sleep Wake Disorders</mesh_term>
	<mesh_term>Parasomnias</mesh_term>
	<mesh_term>Dyssomnias</mesh_term>
	<criteria>Diagnosis of any type of cancer More than 1 primary cancer allowed Has undergone and completed all forms of standard treatment (surgery, chemotherapy, radiation therapy) within the past 2 to 24 months Patients can be on hormones such as Tamoxifen, or monoclonal antibodies like Herceptin Persistent sleep disturbance, as indicated by a response of ≥ 3 when asked to rate their sleep on an 11point scale (0 is equivalent to no sleep disturbance and 10 is the worst possible sleep disturbance) Able to read English 21 years of age or older No prior or concurrent regular (≥ 1 day/week) participation in yoga classes or maintain regular personal practice of any form of yoga within the past 3 months No diagnosis of sleep apnea No concurrent cancer therapy with the exception of hormonal therapy (e.g., tamoxifen citrate) or monoclonal antibodies (e.g., trastuzumab [Herceptin®]) No metastatic cancer</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>cancer-related sleep disturbance</keyword>
	<keyword>fatigue</keyword>
	<keyword>sleep disorders</keyword>
</DOC>